Form 4: Rocket Pharmaceuticals Officer Sells Shares to Cover Tax Obligations
SEC Form 4 Filing
Jonathan David Schwartz, Chief Medical & Gene Therapy Officer at Rocket Pharmaceuticals, sold 801 shares of common stock at $6.446 per share to cover tax withholding obligations related to vesting Restricted Stock Units.
Summary
- On May 20, 2025, Jonathan David Schwartz, Chief Medical & Gene Therapy Officer at Rocket Pharmaceuticals, sold 801 shares of common stock.
- The sale price was $6.446 per share.
- The transaction was executed to cover tax withholding obligations associated with the vesting of Restricted Stock Units (RSUs).
- Following the transaction, Schwartz directly owns 235,255 shares of Rocket Pharmaceuticals common stock, including RSUs that convert to common stock on a one-for-one basis.
Sentiment
Score: 5
Explanation: The document describes a routine transaction (sale of shares to cover taxes) and does not contain any information that would significantly impact investor sentiment positively or negatively.
Industry Context
Sales of shares to cover tax obligations upon vesting of restricted stock units are a common practice among company executives and officers.
Key Dates
| Date | Description |
|---|---|
| 05/20/2025 | Date of the transaction (sale of shares) |
| 05/22/2025 | Date of signature for the Form 4 filing |
Keywords
Rocket Pharmaceuticals, Jonathan David Schwartz, Form 4, Share Sale, Tax Withholding, Restricted Stock Units, RCKT, Officer Transaction
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.